RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Medacta Group Stock

Medacta Group ROE 2024

Medacta Group ROE

0.14

Ticker

MOVE.SW

ISIN

CH0468525222

WKN

A2PFTD

In 2024, Medacta Group's return on equity (ROE) was 0.14, a -14.78% increase from the 0.17 ROE in the previous year.

Medacta Group Aktienanalyse

What does Medacta Group do?

The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide. Medacta Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Medacta Group's Return on Equity (ROE)

Medacta Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Medacta Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Medacta Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Medacta Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Medacta Group stock

What is the ROE (Return on Equity) of Medacta Group this year?

The ROE of Medacta Group this year is 0.14 undefined.

How has the Return on Equity (ROE) of Medacta Group developed compared to the previous year?

The ROE of Medacta Group has increased by -14.78% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Medacta Group?

A high ROE indicates that Medacta Group generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Medacta Group?

A low ROE can indicate that Medacta Group is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Medacta Group affect the company?

A change in ROE (Return on Equity) of Medacta Group can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Medacta Group?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Medacta Group?

Some factors that can influence Medacta Group's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Medacta Group pay?

Over the past 12 months, Medacta Group paid a dividend of 0.27 EUR . This corresponds to a dividend yield of about 0.22 %. For the coming 12 months, Medacta Group is expected to pay a dividend of 0.31 EUR.

What is the dividend yield of Medacta Group?

The current dividend yield of Medacta Group is 0.22 %.

When does Medacta Group pay dividends?

Medacta Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medacta Group?

Medacta Group paid dividends every year for the past 0 years.

What is the dividend of Medacta Group?

For the upcoming 12 months, dividends amounting to 0.31 EUR are expected. This corresponds to a dividend yield of 0.26 %.

In which sector is Medacta Group located?

Medacta Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medacta Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medacta Group from 5/14/2024 amounting to 0.275 EUR, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.

When did Medacta Group pay the last dividend?

The last dividend was paid out on 5/14/2024.

What was the dividend of Medacta Group in the year 2023?

In the year 2023, Medacta Group distributed 0.268 EUR as dividends.

In which currency does Medacta Group pay out the dividend?

The dividends of Medacta Group are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Medacta Group

Our stock analysis for Medacta Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medacta Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.